Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 2/20 | 0.81 |
| ▸ | CCR1 | P32246 | 11/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 3/20 | 0.47 |
| ▸ | CCR3 | P51677 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3813533 | 1.00 | ABCB11 (0.81) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL3813054 | 1.00 | ABCB11 (0.81) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL3809868 | 0.96 | ABCB11 (0.73) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL3809872 | 0.96 | ABCB11 (0.73) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL30172129 | 0.95 | ABCB11 (0.73) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL1950910 | 0.95 | ABCB11 (0.73) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL1683051 | 0.95 | ABCB11 (0.73) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL1949177 | 0.95 | ABCB11 (0.73) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL2016861 | 0.95 | ABCB11 (0.73) | ABCB11CCR1LMNAHRH1CCR3 | |
| SCHEMBL1950911 | 0.95 | ABCB11 (0.73) | ABCB11CCR1LMNAHRH1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306141-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | claimed |
| US-6911458-B2 | Compounds | ASTRA ZENECA (SE) | 2005-06-28 | — | — | US | claimed |
| US-20050090494-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-04-28 | — | — | US | claimed |
| US-20030162772-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2003-08-28 | — | — | US | claimed |
| US-20090306141-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-7528156-B2 | Compounds | ASTRAZENECA AB (SE) | 2009-05-05 | — | — | US | disclosed |
| US-6911458-B2 | Compounds | ASTRA ZENECA (SE) | 2005-06-28 | — | — | US | disclosed |
| US-20050090494-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306141-A1 | Novel Compounds | CHRM2, CHRM1, C1R | ABCB11 113/4885CCR1 573/4885LMNA 2445/4885 |
| US-20050090494-A1 | Novel compounds | CHRM2, CHRM1, C1R | ABCB11 113/4885CCR1 573/4885LMNA 2445/4885 |
| US-20030162772-A1 | Novel compounds | RPS4X, RPS4Y1, MRPS18A | ABCB11 96/4885CCR1 505/4885LMNA 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.